Multiple Manufacturers

ELEVIDYS

Manufacturer:

Multiple Manufacturers

Elevidys HCPCS:

J1413

HCPCS Code Descriptor:

Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose

Category:

J Code

Elevidys NDCs:

60923-0501-10, 60923-0502-11, 60923-0503-12, 60923-0505-14, 60923-0504-13, 60923-0506-15, 60923-0507-16, 60923-0510-19, 60923-0509-18, 60923-0508-17, 60923-0512-21, 60923-0511-20, 60923-0513-22, 60923-0514-23, 60923-0516-25, 60923-0515-24, 60923-0518-27, 60923-0517-26, 60923-0520-29, 60923-0519-28, 60923-0522-31, 60923-0521-30, 60923-0523-32, 60923-0524-33, 60923-0525-34, 60923-0526-35, 60923-0527-36, 60923-0528-37, 60923-0529-38, 60923-0531-40, 60923-0530-39, 60923-0533-42, 60923-0532-41, 60923-0535-44, 60923-0534-43, 60923-0536-45, 60923-0537-46, 60923-0538-47, 60923-0539-48, 60923-0540-49, 60923-0541-50, 60923-0544-53, 60923-0543-52, 60923-0542-51, 60923-0546-55, 60923-0545-54, 60923-0547-56, 60923-0548-57, 60923-0549-58, 60923-0551-60, 60923-0550-59, 60923-0554-63, 60923-0552-61, 60923-0553-62, 60923-0556-65, 60923-0555-64, 60923-0557-66, 60923-0558-67, 60923-0560-69, 60923-0559-68, 60923-0561-70

Primary Type:

Genetic Disorder

Generic/Specialty Status:

Multi-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

60923-0502-11, 60923-0503-12, 60923-0501-10, 60923-0504-13, 60923-0505-14, 60923-0506-15, 60923-0507-16, 60923-0508-17, 60923-0509-18, 60923-0510-19, 60923-0512-21, 60923-0511-20, 60923-0513-22, 60923-0514-23, 60923-0515-24, 60923-0517-26, 60923-0516-25, 60923-0518-27, 60923-0519-28, 60923-0521-30, 60923-0520-29, 60923-0522-31, 60923-0523-32, 60923-0524-33, 60923-0525-34, 60923-0526-35, 60923-0527-36, 60923-0528-37, 60923-0529-38, 60923-0530-39, 60923-0531-40, 60923-0533-42, 60923-0532-41, 60923-0534-43, 60923-0535-44, 60923-0536-45, 60923-0537-46, 60923-0538-47, 60923-0539-48, 60923-0540-49, 60923-0541-50, 60923-0542-51, 60923-0544-53, 60923-0543-52, 60923-0546-55, 60923-0545-54, 60923-0547-56, 60923-0548-57, 60923-0549-58, 60923-0551-60, 60923-0550-59, 60923-0552-61, 60923-0553-62, 60923-0554-63, 60923-0555-64, 60923-0556-65, 60923-0557-66, 60923-0558-67, 60923-0559-68, 60923-0560-69, 60923-0561-70

About Elevidys:

ELEVIDYS is a Genetic Disorder drug manufactured by Sarepta Therapeutics and administered via the Intravenous route of administration. The J Code: J1413 is aligned to the drug ELEVIDYS.

Elevidys is an intravenous gene therapy used to treat Duchenne muscular dystrophy also known as DMD. Patients with DMD have defects in certain proteins in their muscles. Elevidys works by helping the body make the protein Elevidys micro-dystrophin, which can contain copies of the defective sections of proteins. DMD can causes symptoms such as difficulty walking and running, fatigue, learning disabilities, frequent falling, and heart issues.

ACCESS PRICING AND MORE BY REGISTERING

J1413 Added Date:

January 1, 2024

J1413 Effective Date:

January 1, 2024

J1413 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Elevidys billing and coding information.
Elevidys patient assistance information can be found through SareptAssist at the URL: https://www.sarepta.com/sareptassist
Our team is still working to identify a prescribing information source for ELEVIDYS
Our team has not yet identified a source of side effects information for ELEVIDYS. Please check back in a few weeks.